// App-Quantinova.ai

: Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy

Researchers

Presenter

  • Qayyim Said

Principal Investigators

  • Lincy S Lal

  • Katherine Andrade

  • Brigette Nezami

  • J. Anthony Graves

  • Anuja Roy

  • Adam Cuker

Medical Centers

  • Oncology and Hematology, Novartis, East Hanover, NJ

  • Optum, Missouri City, TX

  • Optum, Eden Prairie, MN

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Abramson Cancer Center and Dept of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Locations

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Transient Ischemic Attack

  • Immune thrombocytopenia

  • Myocardial infarction

  • Deep vein thrombosis

  • Pulmonary embolism

  • Thrombocytopenia

  • Venous thrombosis

  • Anemia

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Immune globulin

  • Eltrombopag

  • Romiplostim

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved